Withhold IS (B cell depletion therapy)

( DrugBank: - / KEGG DRUG: - )

7 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
35	Pemphigus	1
46	Malignant rheumatoid arthritis	1
49	Systemic lupus erythematosus	1

ID	Disease name (Link within this page)	Number of trials
50	Dermatomyositis	1
51	Scleroderma	1
107	Juvenile idiopathic arthritis	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last

35. Pemphigus

Clinical trials : 99 / Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last

50. Dermatomyositis

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last

51. Scleroderma

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last

107. Juvenile idiopathic arthritis

Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccin ...	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis ( ...	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States

First Previous1Next Last